LSA
MRNA icon

L & S Advisors’s Moderna MRNA Stock Holding History

L & S Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.94M Buy
+41,976
New +$2.17M 0.3% 98
2022
Q3 		– Sell
-2,214
Closed -$316K – 258
2022
Q2 		$316K Buy
2,214
+404
+22% +$57.7K 0.05% 181
2022
Q1 		$312K Sell
1,810
-737
-29% -$124K 0.04% 237
2021
Q4 		$647K Sell
2,547
-331
-12% -$96.8K 0.07% 203
2021
Q3 		$1.11M Sell
2,878
-10,081
-78% -$3.72M 0.12% 192
2021
Q2 		$3.04M Buy
12,959
+7,801
+151% +$1.39M 0.33% 93
2021
Q1 		$675K Sell
5,158
-23,169
-82% -$3.36M 0.08% 235
2020
Q4 		$2.96M Sell
28,327
-17,444
-38% -$1.76M 0.34% 97
2020
Q3 		$3.24M Buy
45,771
+8,369
+22% +$584K 0.45% 78
2020
Q2 		$2.4M Sell
37,402
-22,354
-37% -$1.22M 0.36% 81
2020
Q1 		$1.79M Buy
+59,756
New +$1.37M 0.34% 70

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

L & S Advisors's MRNA Position: Q2 2026 in Review

L & S Advisors opened a new position in Moderna (MRNA) in Q2 2026: 41,976 shares worth $2.94M. The stake represents 0.3% of the portfolio and ranks #98 among its holdings. This is a return to the name: L & S Advisors previously reported a position in MRNA as recently as Q2 2022.

L & S Advisors first reported a position in MRNA in Q1 2020 and has held it in 11 quarters since. The position peaked at $3.24M in Q3 2020. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • L & S Advisors held 41,976 shares of Moderna worth $2.94M as of Q2 2026.
  • Moderna was a new L & S Advisors position in Q2 2026.
  • Moderna made up 0.3% of L & S Advisors's portfolio in Q2 2026, its #98 holding.
  • L & S Advisors first reported a position in Moderna in Q1 2020 and has held it in 11 quarters since.
  • L & S Advisors's Moderna position peaked at $3.24M in Q3 2020.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on L & S Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.